DKSH Business Unit Healthcare, a leading partner for healthcare companies seeking to grow their business in Asia, has signed a five year agreement with Bayer HealthCare, a specialist in research, development, manufacturing and marketing of general and specialty medicine, to provide importation, custom clearance, logistics and physical distribution as well as credit and collection services for both Bayer’s Pharmaceuticals and Consumer Care Divisions.
DKSH Healthcare has supported Bayer’s growth in Cambodia since 2003. The company furthermore provides Market Expansion Services for Bayer’s Consumer Care and Pharmaceuticals Divisions in Thailand and China.
“For over a decade DKSH has supported Bayer in our growth in the market here. Our decision to extend our partnership in Cambodia is based on their broad capabilities and expertise in innovative value-added services, their dedication to quality and compliance as well as their deep market and industry knowledge,” said Maline Srun, branch manager of Bayer (Cambodia) Branch.
“The extension of our partnership with Bayer HealthCare in Cambodia for another five years strengthens our position as preferred Market Expansion Services partner for small and medium sized as well as big multinational pharmaceuticals companies who want to grow their business in Cambodia,” commented Nicolas Chabanier, general manager, Business Unit Healthcare, DKSH Cambodia.
The agreement between DKSH and Bayer HealthCare in Cambodia demonstrates DKSH’s ability to roll-out success stories from country to country. The agreement will further strengthen DKSH’s market position and gradually contribute to the Group’s overall profitability.
DKSH is the leading market expansion services provider with a focus on Asia. As the term “market expansion services” suggests, DKSH helps other companies and brands to grow their business in new or existing markets.
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials and is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen.
This article originally appeared on Pharmabiz.com